| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Friday, October 27, 2017 AbbVie has posted positive phase 3 psoriasis data on potential blockbuster risankizumab. The IL-23 antibody easily outperformed Johnson & Johnson’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year. |
|
|
Top Stories Of The Week Friday, October 27, 2017 Gilead’s doing its best to move away from hepatitis C. But as usual, that topic dominated the discussion on its third-quarter earnings call—and it wasn’t a positive discussion. Wednesday, November 1, 2017 After a failed trial in May, AstraZeneca hoped tralokinumab could pass subpopulation tests and make it to the finish line, but it wasn’t meant to be. Wednesday, November 1, 2017 Heading into Allergan’s third-quarter conference call, executives knew investors were skittish about the prospect of Restasis generics. So they spelled out their solution loud and clear: Cost cuts are coming, and “rapidly.” Wednesday, November 1, 2017 When Pfizer was preparing to shell out $15 billion for regulatory-challenged Hospira, executives assured investors and regulators that they had the skills to quickly resolve issues at the plants of the sterile injectables specialist. But it has turned out to be a harder job than they anticipated, taking a toll on Pfizer’s earnings and creating serious problems for some of its clients along the way. Thursday, October 26, 2017 As public health officials work to address the opioid crisis, scientists are laboring to develop alternatives that can relieve pain without causing dependency and other adverse side effects. This week a team at Indiana University reported promising results in mice for a novel compound that works by enhancing the brain’s natural ability to produce painkillers. Tuesday, October 31, 2017 Working to recover from a damaging cyberattack, Merck reported that its star HPV vaccine missed sales expectations in the third quarter as it had to borrow from the CDC's stockpile to fulfill orders. Friday, October 27, 2017 Butterfly Network’s ultrasound-on-a-chip technology snagged the FDA nod for 13 applications, the broadest clearance to date for an ultrasound transducer. The pocket-sized transducer, which plugs into an iPhone, would expand the availability of diagnostic ultrasound imaging. Wednesday, November 1, 2017 Now that Bristol-Myers Squibb’s Opdivo has safely posted growth in 2017, all eyes are on what the drug can pull off next year. Its move into a larger kidney cancer market will be central to that equation. Thursday, November 2, 2017 Major CRO player Pharmaceutical Product Development (PPD) has won a lucrative seven-year government contract in infectious disease. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: SAS In the quest to understand how a therapeutic intervention performs in actual use – in real medical practice outside the controlled environment of clinical trials – many life sciences organizations are stymied. Download now to read more. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST: Join this webinar to discover tested and proven solutions to manage vacancies. Presented by Tyler Cowan, VP, Client Solutions, Ashfield US, you’ll learn how to maintain and build momentum in field sales despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. |
|
